In a clinical report issued by the American Academy of Pediatrics and published online Feb. 18 in Pediatrics, recommendations ...
The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.
The lab of Dr. Mark Magnuson, Louise B. McGavock Professor and professor of molecular physiology and biophysics at Vanderbilt ...
Prev Cardiol. 2003;6(1) © 2003 Le Jacq Communications, Inc. Cite this: The Intestinal Absorption of Biliary and Dietary Cholesterol as a Drug Target for Lowering the ...
The Biliary Atresia market growth is driven by factors like increase in the prevalence of Biliary Atresia, investments in ...
Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer ...
Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
Biliary tract cancer occurs in the bile ducts ... had more good news with the drug today from a clinical trial in renal cell carcinoma, a form of kidney cancer. In the KEYNOTE-564 study, Keytruda ...
Biliary tract cancer occurs in the bile ducts ... The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which ...